Methylene Blue Treatment of COVID-19
- Registration Number
- NCT04635605
- Lead Sponsor
- Fondazione Epatocentro Ticino
- Brief Summary
Despite enormous progress in understanding COVID-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved. Repurposing of well known, widely available drugs represent an attractive approach to speed up availability of active treatments. Such substances as i.e. hydroxychloroquine and others, are already under investigation and in widespread off label use. For many reasons Methylene blue (MB), the oldest synthetic substance in medicine (1876 synthesized by BASF) is such a promising candidate for an active treatment against SARS-CoV-2 infected people and for COVID-19 patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 64
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description control group Control Test The control intervention would be the group receiving 100 mg placebo capsules twice a day for five consecutive days Methylene Blue Methylene Blue Methylene Blue 100 mg capsules. Patients will receive Methylene blue (MB) capsules of 100mg every 12 hours for a total of 5 days.
- Primary Outcome Measures
Name Time Method to compare the viral load kinetics in the enrolled patients with a SARS-CoV-2 positive nasopharyngeal swab demonstrating a reduction of the area under the curve day 0- day 21 of at least 25% day 0 - day 21 As primary outcome we will measure the viral load kinetics in the enrolled patients. This means the viral load (expressed as cycled of replication with the PCR method and the number of RNA copies) at baseline and at each scheduled timepoint of the study
- Secondary Outcome Measures
Name Time Method Safety and tolerability of the administered drug are registered as "adverse events", which are all symptoms related or supposed to be related to the drug that appeared after the drug intake and were NOT present at baseline or before 3, 6, 9, 12, 15, 21, 28 and 84 days after diagnosis Safety and tolerability of the administered drug are registered as "adverse events", which are all symptoms related or supposed to be related to the drug that appeared after the drug intake and were NOT present at baseline or before Adverse events are expressed as present (1) or absent (0), in the dedicated data sheet which will be collected at each scheduled visit
To calculate the percentage of patients clearing SARS-CoV-2 by 3, 6, 9, 12, 15 and 21 days after diagnosis 3, 6, 9, 12, 15 and 21 days after diagnosis We report the number of patients (expressed as percentage) with negative oro-pharyngeal swab at the scheduled time-points
To calculate the percentage of patients alive at 28-days and 84-days We calculate the number of patients (expressed as percentage) still alive at day 28 and 84 of samples collection
To calculate the percentage of patients having a reduction of viral load of > 2 log by day 3 day 3 We calculate the number of patients (expressed as percentage) that have a decreased viral load (expressed as RNA copies) greater than 2 log by day three
To calculate the percentage of patients having a poor outcome as measured by the need of hospitalization for COVID-19 3, 6, 9, 12, 15, 21, 28 and 84 days after diagnosis We calculate the number of patients (expressed as percentage) that need hospitalization due to COVID-19, within the timeframe of the study
To measure the compliance by calculating the number of capsules taken by the patient and the overall number of patients who complete the treatment 3, 6, 9, 12, 15 and 21 days after diagnosis We calculate the number of pills (expressed as absolute number) taken by each enrolled patient during the study
Trial Locations
- Locations (1)
Fondazione Epatocentro Ticino
🇨ðŸ‡Lugano, Ticino, Switzerland